Association analysis of the 5-HT6 receptor polymorphism C267T in Alzheimer's disease
Section snippets
Acknowledgements
This study is supported by grants from the National Science Committee (NSC88–2314-B-075–064) and National Health Research Institute (DOH-88-HR-604).
References (9)
- et al.
Immuno-localization of serotonin 5-HT6 receptor-like material in the rat central nervous system
Brain Res.
(1997) - et al.
Antisense oligonucleotide I.C.V. affects rat performance in the water maze and feeding
J. Psychopharmacol.
(1997) - et al.
Determination of the role of the 5-ht6 receptor in the rat brain: a study using antisense oligonucleotides
J. Pharmacol. Exp. Ther.
(1995) - et al.
Quantitative RT-PCR distribution of serotonin 5-HT6 receptor mRNA in the central nervous system of control or 5,7-dihydroxytryptamine-treated rats
Synapse
(1996)
Cited by (55)
Functional pharmacogenetics of serotonin receptors in psychiatric drug action
2020, Handbook of Behavioral NeuroscienceCitation Excerpt :Vogt et al. (2000) identified six polymorphisms in the gene of 5-HT6 receptor, of which two (a silent 267 C/T in exon 1 (rs 1805054) and a trinucleotide repeat polymorphism ([GCC](2/3)) in the 5′-upstream region of the gene) have been studied more extensively. An association study of these polymorphisms with susceptibility to suicide was negative (Okamura et al., 2005), and a significant association between the 5-HT6 receptor 267 C/T polymorphism with Alzheimer's disease (Tsai, Liu, Liu, Wang, & Hong, 1999) has not been replicated (Thome et al., 2001). Pharmacogenetic studies of the 267 C/T polymorphism and clozapine response in schizophrenia have given contradictory results.
Serotonin 6 receptor gene is associated with methamphetamine-induced psychosis in a Japanese population
2011, Drug and Alcohol DependenceCitation Excerpt :Several studies have suggested that it may affect translation through the secondary structure and stability of the mRNA, or be in LD with a functional variant. Therefore, genetic association studies of psychiatric disorders such as schizophrenia (Chiu et al., 2001; Shinkai et al., 1999; Tsai et al., 1999a; Vogt et al., 2000), bipolar disorder (Hong et al., 1999), major depressive disorder (MDD) (Hong et al., 1999) and Alzheimer's disease (Alvarez-Alvarez et al., 2003; Kan et al., 2004; Liu et al., 2001; Tsai et al., 1999b), and pharmacogenic studies of the antipsychotic response in schizophrenia (Ikeda et al., 2008) have so far investigated only rs1805054 in HTR6. However, we found an association of rs6693503 but not rs1805054 (C267T) with METH-induced psychosis patients in this single marker association study.
Highly potent, non-basic 5-HT<inf>6</inf> ligands. Site mutagenesis evidence for a second binding mode at 5-HT<inf>6</inf> for antagonism
2010, Bioorganic and Medicinal Chemistry LettersFunctional Pharmacogenetics of Serotonin Receptors in Psychiatric Drug Action
2010, Handbook of Behavioral NeuroscienceCitation Excerpt :Vogt et al. (2000) identified six polymorphisms in the gene of the 5-HT6 receptor, of which two (a silent 267C/T in exon 1 and a trinucleotide repeat polymorphism ([GCC](2/3)) in the 5′-upstream region of the gene) have been studied more extensively. An association study of these polymorphisms with susceptibility to suicide was negative (Okamura et al., 2005), and a significant association between the 5-HT6 receptor 267C/T polymorphism with Alzheimer's disease (Tsai et al., 1999) has not been replicated (Thome et al., 2001). Pharmacogenetic studies of 267C/T polymorphism and clozapine response in schizophrenia have given contradictory results.